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Background: Patients discharged after an acute coronary syndrome (ACS) have substantial risk
of recurrent ischemic events or dying.
Hypothesis: A difference may exist in risk predictors for all-cause mortality and ischemic events
between year 1 and 2 of follow-up post-ACS.
Methods: EPICOR (NCT01171404) was a prospective, international, real-world cohort study of
consecutive patients hospitalized for ACS within 24 hours of symptom onset and surviving to
discharge. Total of 10 568 patients were enrolled (555 hospitals; 20 countries) and followed-up
for 2 years. From these, 4943 were admitted with ST-elevation myocardial infarction (STEMI)
and 5625 with non-ST-elevation ACS (NSTE-ACS). Potential baseline predictors of major
adverse cardiac and cerebrovascular events (MACCE; death, non-fatal myocardial infarction
[MI], non-fatal stroke) were evaluated in year 1 and 2 post-discharge.
Results: MACCE incidence per 100 person-years at risk within and after 1 year was 5.3 vs 3.6,
primarily death (4.1 vs 2.3), with no significant differences for MI or stroke. Older age, lack of
coronary revascularization, raised creatinine, low hemoglobin, previous cardiac disease, previous
chronic obstructive pulmonary disease, raised glucose, male sex, and geographic region were risk
factors for MACCE in both year 1 and 2. By contrast, low ejection fraction, poorer quality of life,
low body mass index (BMI) <20 kg/m2, in-hospital cardiac complications, and Killip class lost
predictive power after 1 year.
Conclusion: We observed continuous MACCE risk during 2 years of follow-up after discharge
for ACS, with greater mortality within the first year. Specific predictors at discharge for events
after 1 year could not be identified.
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1 | INTRODUCTION
Prognosis of patients with acute coronary events (ACS) has
improved over the past decade owing to the use of guideline-
recommended therapies, such as early revascularization, antithrom-
botic therapies and other secondary prevention measures.1–3
Consequently, the proportion of stable post-ACS is growing and will
represent a clinical challenge in the coming decades. Most data
focus on events and predictors within the first year after an ACS,4,5
whereas data describing events 1 year post-ACS are scarce and
limited to selected groups from clinical trials.6,7 However, it is
known that patients surviving the first year after an ACS remain at
high risk for dying or having future ischemic events.3,8,9 Risk for fur-
ther ischemic events and death is compounded by baseline charac-
teristics and a high variability in management practice both at
discharge and subsequently.3,8 Risk stratification to guide secondary
prevention therapies seems crucial for the decision-making pro-
cess.4,10 The assessment of individual patient risk at hospital dis-
charge provides an opportunity to potentially guide appropriate
management strategies following discharge.11,12
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Little is known about the type of ischemic events occurring early
and later after hospital discharge in patients post-ACS. Similarly, there
is a poor understanding of the prognostic value of baseline clinical fea-
tures at different time points of the post-ACS follow-up. Using patient
data from the EPICOR (long-term follow-up of antithrombotic man-
agement patterns In acute CORonary syndrome patients) registry
(NCT01171404),13 we aimed to assess which predictors are associ-
ated with mortality and ischemic events within 1-year follow-up of an
ACS event (year 1) and during a subsequent 1-year follow-up (year 2)
in those patients who were event-free during year 1. We tested
17 clinical predictors, which had been previously described in the EPI-
COR 2-year mortality risk score.14
2 | METHODS
2.1 | Study design
EPICOR is a prospective, international, observational, real-world prac-
tice, cohort study comprising consecutive patients, hospitalized for an
ACS within 24 hours of symptom onset who survived to hospital
discharge.13
In total, 10 568 patients were enrolled from 555 hospitals in
20 countries across Europe and Latin America (September 2010 to
March 2011); 4943 were diagnosed with ST-segment elevation myo-
cardial infarction (STEMI) and 5625 with non-ST-segment elevation
ACS (NSTE-ACS, comprising non-STEMI and unstable angina [UA]).
The study rationale and design have been described in detail
elsewhere.13
2.2 | Study population
The main inclusion criteria for the EPICOR registry were: hospitaliza-
tion within 24 hours of symptom onset of the index event and a final
diagnosis of STEMI or NSTE-ACS at discharge, age ≥18 years, and
written informed consent. Patients were excluded if they had a “sec-
ondary” ACS (precipitated by, or occurring as, a complication of sur-
gery, trauma, gastrointestinal bleeding or percutaneous coronary
intervention [PCI], or occurring during hospitalization for other rea-
sons). Other exclusion criteria included any condition/circumstance
considered likely to limit the completion of follow-up, any serious/
severe comorbidities limiting life expectancy to less than 6 months, or
previous enrolment in EPICOR, or another clinical trial.
2.3 | Follow-up and event definition
Patients were followed up by centralized telephone interviews by
trained native speakers of each patient's language, who were super-
vised by a Direct Patient Contact Manager. Patients were interviewed
at 6 weeks after the index event and then every 3 months up to
24 months. Interviews included questions related to the occurrence
of events, ischemic and/or bleeding; planned and unplanned hospitali-
zations, interventions or visits to the emergency room or other physi-
cians (including dentists); treatment changes, including any planned/
unplanned treatment interruptions; other healthcare resource utiliza-
tion; and quality of life.
Events were recorded through specific questionnaires in which
hospitalizations or emergency department visits were first documen-
ted. In such cases, interviewers were asked to collect all relevant clini-
cal information (medical reports) from the patient, hospital physicians,
or general practitioners. Whenever necessary, the primary study
investigator was contacted to obtain confirmation or any clarification
regarding the identified event.
All cardiovascular events reported by patients, relatives, or physi-
cians were recorded together with specific information regarding each
particular event, but only events in which a medical record with a spe-
cific diagnosis was available were computed. Therefore, event rates
were calculated according to diagnoses reported in medical records.
In this analysis, patient follow-up was divided into two periods:
(a) first year follow-up after hospital discharge from index ACS (year
1); and (b) second year (year 2; patients event-free during year 1)
follow-up. Figure 1 depicts the flowchart of patients along the study.
The primary endpoint during each time period was the composite
of major adverse cardiac and cerebrovascular events (MACCE), defined
as death, non-fatal myocardial infarction (MI) (non-fatal STEMI or non-
fatal non-NSTEMI), and non-fatal primary ischemic stroke.
2.4 | Predictors of 2-year mortality at hospital
discharge after ACS
Relationships between outcomes and known baseline risk factors at
discharge were also investigated. We investigated the baseline risk
factors described in the 2-year mortality risk score derived from the
EPICOR and EPICOR Asia cohorts14 to describe their relationship with
the outcome in our two time-period cohorts. This risk model contains
18 predictors of 2-year mortality: age, low ejection fraction at admis-
sion, no coronary revascularization, or thrombolysis, elevated serum
creatinine at admission, poor EuroQol-5 dimensions score (EQ-5D,
which is a patient questionnaire assessing five parameters: mobility,
self-care, ability to perform usual activities, pain/discomfort, and
FIGURE 1 Patient flowchart. Abbreviations: ACS, acute coronary
syndrome; MACCE, major adverse cardiac and cerebrovascular events
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anxiety/depression as “no problem” for zero points, “moderate” for
one point or “a severe limitation” for two points15), low hemoglobin,
previous cardiac disease (MI, angina, heart failure, or atrial fibrillation),
previous chronic obstructive pulmonary disease, elevated blood glu-
cose at admission, on diuretics at discharge, male sex, lower educa-
tional level, on aldosterone inhibitor at discharge, body mass index
(BMI), in-hospital cardiac complications (MI or recurrent ischemia, car-
diogenic shock, heart failure or any arrhythmia), diagnosis of STEMI,
Killip class and region. The development and performance of the
model have been described elsewhere.14 This risk score has been used
for adjustment in previous studies.16,17
All risk factors included in this score were used to describe
patient characteristics and in-hospital management in our study. We
also used risk stratification categories to rank patients across six risk
subgroups, according to 2-year mortality risk: 1 to 4 representing the
first 4 quintiles of patients, with groups 5 and 6 representing the top
2 deciles of risk.
2.5 | Statistical analysis
Three groups were defined according to time of first-event:
(a) patients without events during follow-up; (b) patients with an
event during first-year follow-up; and (c) patients with an event during
the second-year follow-up, who were event-free during the first year.
Patient characteristics and in-hospital management across groups
2 and 3 were compared using χ2 test or student t test as appropriate.
Trend tests were used to compare ordinal risk factors between groups
2 and 3. Continuous parameters are presented as mean (SD) and cate-
gorical data are expressed as percentages.
Incidence rates for the primary endpoint are presented per
100 person-years at risk. Stratified rate ratios for each time period
(year 1 vs 2) were estimated and compared using the Mantel-Haenszel
test. Cumulative probabilities of the primary composite endpoint
MACCE during each time period are presented as Kaplan-Meier
curves. A multivariable Cox proportional hazard regression including
all variables in the 2-year mortality risk score14 was performed to
evaluate the association of these baseline risk factors with MACCE in
each time period. Cumulative mortality and MACCE, stratified by
six risk groups (based on EPICOR 2-year mortality risk score)14 was
calculated for each follow-up time period, and P values were obtained
using the log-rank test for equality of survivor functions. Relationships
between MACCE and known baseline risk factors are presented as
hazard ratio (HR) with its 95% confidence interval (CI).
All P values were two-sided and values of <0.05 were considered
as statistically significant. All statistical analyses were performed using
STATA software, version 13.1 (Stata Corp, College Station, Texas).
3 | RESULTS
3.1 | Descriptive MACCE events across first- and
second-year follow-up
In total, 815 patients experienced MACCE during the 2-year follow-
up, with more patients experiencing an event during year 1 (n = 514)
compared with year 1 event-free patients experiencing an event dur-
ing year 2 (n = 301), P < 0.001. The difference in the outcome was
driven by mortality, as death occurred more often during the first
year, while non-substantial differences in non-fatal event rates were
found between year 1 and 2. Kaplan-Meier estimates of MACCE and
incidence rate of events (by event type) for each time period are
shown in Figure 2. MACCE and death incidence rates are presented in
Supporting Information Table S1. Of note, 12 patients presented a
subsequent event during the year 2 follow-up.
3.2 | Baseline characteristics and in-hospital
management for year 1 and 2
Baseline characteristics and in-hospital management for populations
with events (year 1 or 2) or with no events are shown in Table 1. No
differences were observed in these variables between patients with
an event during year 1 and those with an event during year 2 of
follow-up. Table S2 shows event rates for each variable during each
time period.
Figure 3 depicts Kaplan-Meier estimates of the risk for MACCE
and MACCE incidence rates during each time period, according to the
occurrence of revascularization (PCI, coronary artery bypass graft or
thrombolysis) in patients with NSTE-ACS and STEMI, respectively.
3.3 | Risk factors associated with MACCE during
first-year follow-up vs second-year follow-up
Results of multivariable Cox proportional hazard models to elucidate
those risk factors associated with MACCE in each time period are pre-
sented in Table 2. Briefly, in order of predictive strength, older age,
male sex, certain geographic regions, lack of coronary revasculariza-
tion or thrombolysis, higher creatinine, prior cardiac disease, prior
chronic obstructive pulmonary disease (COPD), and higher glucose
values were observed as risk factors for MACCE during both year
1 and 2 (Table 2). By contrast, lower ejection fraction, low BMI
(<20 kg/m2), poorer quality of life, use of an aldosterone inhibitor at
discharge, in-hospital cardiac complications, and Killip class were not
observed as risk factors after year 1. The use of diuretics at discharge
tended to show a slightly higher degree of association with MACCE
during the second year follow-up in comparison with the first year.
Neither education nor diagnosis of STEMI were related to MACCE in
any of the time periods being studied.
Cumulative probability of MACCE stratified by six risk groups
(based on the 2-year mortality EPICOR risk score) was estimated for
each follow-up time period, as illustrated in Figure S1. Table S3 shows
the occurrence of MACCE in the different risk groups based on the
EPICOR 2-year mortality risk score by type of ACS (STEMI vs NSTE-
ACS) for each time period.
4 | DISCUSSION
Using a prospective, international, real-world cohort study of consecu-
tive patients hospitalized for an ACS within 24 hours of symptom
onset who survived to discharge (EPICOR registry), we observed a
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continuous incidence of MACCE during the 2-year follow-up,
although there was a higher mortality during the first year compared
than the second year of follow-up, an observation that is consistent
with other cohort studies.3 By contrast, the rate of non-fatal MI and
non-fatal stroke did not substantially differ between the first and sec-
ond year after ACS. Remarkably, we found that absence of revascular-
ization (PCI, coronary artery bypass graft or thrombolysis) is
associated with a higher incidence of MACCE not only during year
1 but also in year 2. Using the 18 predictors of the EPICOR risk score
model, we failed to identify specific risk factors associated with poor
prognosis beyond 1 year post-ACS. There was a tendency for the use
of diuretics at discharge to be associated with MACCE during year
2, but not year 1 (P = 0.02 and 0.07, respectively), but no strong con-
clusions can be drawn from this observation. Some differences were
found across factors between year 1 and 2: half of them were signifi-
cantly associated to both time periods, while among the remaining,
most of them were only associated to outcomes in year 1.
Data from a large Swedish registry including 108 315 post-MI
patients with long-term follow-up revealed a cumulative rate of a car-
diovascular composite endpoint (cardiovascular death, recurrent MI,
and stroke) of 18.3% in the first year after MI, 9.0% in the subsequent
year and 20.0% in the following 3 years.3 Similarly, the APOLLO
study,18 which recruited 1-year post-MI patients aged ≥65, showed
an adjusted risk mortality over the subsequent 3 years ranging from
12.8% to 19.5% across four different countries. Data from
randomized clinical trials show substantially lower mortality rates in
the first year after the index MI.19,20 For example, in the Prevention
of Cardiovascular Events in Patients with Prior Heart Attack Using
Ticagrelor Compared to Placebo on a Background of Aspirin-
Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) study,
the 3-year mortality risk was 5.2% in the aspirin group.6 By contrast,
the rates of non-fatal MI and non-fatal stroke did not substantially dif-
fer between the first and second year after ACS. These findings are
also in line with observations from previous reports of long-term
follow-up after ACS,3 and might be explained because high-risk
patients often experience events or die during the first year of MI and
are therefore no longer at risk for non-fatal events. Our data indicate
that despite current treatments, there is a residual risk in a large num-
ber of patients after ACS, even after an uneventful first year after dis-
charge. The question about the risk of ischemic events beyond a post-
ACS period of stabilization might be answered by an ongoing trial:
long-term risk, clinical management, and healthcare resource utiliza-
tion of stable coronary artery disease in post-MI patients (TIGRIS,
NCT01866904). This large trial is a multicenter, observational, pro-
spective, longitudinal study enrolling patients with a history of MI 1 to
3 years before study entry and who are at high risk of developing
atherothrombotic events.21
In our study, the type of ACS (STEMI vs NSTE-ACS) was not
associated with a higher risk of events at either year 1 or 2. How-
ever, lack of revascularization, a recognized independent risk
FIGURE 2 Kaplan-Meier estimate of the risk of major adverse cardiac and cerebrovascular events (MACCE) at (A) year 1 of follow-up after
discharge, (B) year 2 of follow-up (among year 1 MACCE-free patients), and (C) incidence rate by event type. EPICOR had a total duration of
24 months, with the last interview conducted within 2 weeks. Patients who completed study follow-up were censored starting at 23.5 months.
Time at risk (100 person-years): year 1, 9748.4; year 2, 8348.7. Patients with non-fatal event in year 1 were excluded from follow-up in year
2. Year-1 follow-up, 10 568 patients at risk at start; year-2 follow-up, 9209 patients at risk at start. aMACCE, defined as death, non-fatal MI and
non-fatal stroke. bPer 100 person-years at risk. cYear 1 follow-up as reference group. Abbreviations: CI, confidence interval; EPICOR, long-term
follow-up of antithrombotic management patterns In acute CORonary syndrome; MACCE, major adverse cardiac and cerebrovascular events; MI,
myocardial infarction
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factor for MACCE,14 was a major risk factor for future events
regardless of type of ACS. This might be related both to the coro-
nary anatomy and patient-related risk factors but underscores the
importance of revascularization for long-term ischemic risk. Our
findings agree with previous studies, which also showed that
patients who did not undergo revascularization have an increased
risk of subsequent cardiovascular events,22 either in year 1 or year
2.3 Although the benefit of reperfusion has been well described in
patients with STEMI, the long-term impact of revascularization in
NSTE-ACS patients is less established.23 Our observations point to
TABLE 1 Baseline characteristics and in-hospital management according to time of first major adverse cardiac and cerebrovascular events
(MACCE)
Variable
Patients with no
events
Patients with a year
1 event
Patients with only a year
2 event
P
valuea
N 9752 514 301 —
Age in years, mean (SD) 61.2 (12.1) 68.5 (12.1) 67.3 (12.4) 0.201
Male sex, n (%) 7334 (75.2) 368 (71.6) 218 (72.4) 0.799
Education, n (%) — — — 0.949b
No formal 414 (6.1) 43 (11.7) 20 (9.5) —
Primary 2312 (34.0) 150 (40.8) 97 (46.2) —
Secondary 3081 (45.3) 130 (35.3) 64 (30.5) —
University 997 (14.7) 45 (12.2) 29 (13.8) —
Region, n (%) — — — 0.024
Northern Europe 3557 (36.5) 132 (25.7) 92 (30.6) —
Southern Europe 2167 (22.2) 105 (20.4) 65 (21.6) —
Eastern Europe 2174 (22.3) 148 (28.8) 58 (19.3) —
Latin America 1854 (19.0) 129 (25.1) 86 (28.6) —
Ejection fraction at admission, n (%) — — — <0.001a
≥40% 8110 (90.6) 340 (71.1) 225 (81.6) —
<40% 670 (7.5) 80 (16.7) 37 (13.4) —
<30% 167 (1.9) 58 (12.1) 15 (5.1) —
BMI <20 kg/m2, n (%) 133 (1.6) 16 (3.8) 7 (2.8) 0.517
No coronary revascularization or thrombolysis, n
(%)
7136 (73.3) 267 (52.1) 177 (59.0) 0.055
Creatinine at admission, mg/dL, mean (SD) 1.03 (0.48) 1.35 (1.02) 1.25 (0.92) 0.164
EQ-5D, n (%)c — — — 0.094b
0 4505 (47.3) 158 (31.4) 112 (37.8) —
1 2056 (21.6) 98 (19.5) 52 (17.6) —
≥2 2954 (31.1) 247 (49.1) 132 (44.6) —
Hemoglobin at admission, g/dL, n (%) — — — 0.435b
<11 359 (3.9) 49 (10.4) 26 (9.2) —
<13 1582 (17.3) 132 (27.9) 74 (26.2) —
≥13 7180 (78.7) 292 (61.7) 182 (64.5) —
Prior cardiac disease, n (%) 2484 (25.8) 261 (51.9) 159 (53.0) 0.760
Previous COPD, n (%) 574 (6.0) 66 (13.2) 43 (14.4) 0.617
Glucose, mg/dL at admission, mean (SD) 142.0 (78.7) 164.0 (92.0) 164.0 (90.7) 0.996
Diuretics at discharge, n (%) 1665 (17.2) 201 (39.2) 100 (33.6) 0.110
Aldosterone inhibitor at discharge, n (%) 751 (7.7) 102 (19.9) 45 (15.2) 0.090
In-hospital cardiac complications, n (%) 1687 (17.4) 171 (33.4) 85 (28.2) 0.126
Diagnosis of STEMI, n (%) 4640 (47.6) 193 (37.6) 110 (36.5) 0.775
Killip class, n (%) — — — 0.002b
I 7744 (88.4) 327 (70.8) 225 (82.4) —
II 722 (8.2) 85 (18.4) 27 (9.9) —
III-IV 296 (3.4) 50 (10.8) 21 (7.7) —
Key characteristics based on the 2-year risk score based on EPICOR and EPICOR Asia population.14 Patient characteristics and in-hospital management
across groups 2 and 3 were compared using χ2 test or student t test as appropriate.
a Patients with years 1 vs 2 events.
b Test for trend
c The EQ-5D is a patient-reported Quality of life questionnaire (EQ-5D) measured at discharge.
Abbreviations: BMI, body mass index; CABG: coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; EQ-5D, EuroQol five-dimension
questionnaire; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.
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FIGURE 3 Kaplan-Meier estimates of the risk for major adverse cardiac and cerebrovascular events (MACCE), and MACCE incidence rates
according to the occurrence of revascularization (percutaneous coronary intervention [PCI], coronary artery bypass graft [CABG] or thrombolysis),
in non-ST-segment elevation acute coronary syndrome (NSTE-ACS) (upper panel) and ST-elevation myocardial infarction (STEMI) patients (lower
panel). Log-rank estimates. Abbreviations: ACS, acute coronary syndrome; CI, confidence interval
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a continuous lower risk for MACCE in revascularized in patients
with NSTE-ACS.
There is a need to identify risk factors for long-term events to
inform decisions on the duration and intensity of secondary preven-
tion measures.24 By using valid clinical prediction models, clinicians
can accurately advise patients about their prognosis and how this
translates into treatment decisions. We used the EPICOR 2-year mor-
tality risk score model and applied it for the identification of specific
risk factors for MACCE during first and second year post-ACS. We
were unable to identify a relevant subset of risk factors for year
2 events. This information is relevant in the light of studies showing
that prolonging dual antiplatelet therapy (DAPT) for >12 months can
improve outcomes,6,25 and that analysis of prolonged DAPT use in
EPICOR is ongoing. Although it is sensible that some risk factors
under investigation were associated with outcomes beyond year
1 because of their “acute” effect (ie, Killip class, in-hospital cardiac
complications or ejection fraction), we cannot rule out a lack of power
for detecting an effect in year 2, in which there were fewer outcomes.
Previous attempts to identify specific risk factors for “stable” post-
ACS have also failed — the Swedish registry reported the same risk
factors (older age, diabetes, lack of revascularization for the index MI,
and a prior history of MI, stroke, heart failure or UA) for ischemic
events in the 2 follow-up periods.3
4.1 | Strengths and limitations
There are several methodological limitations that should be men-
tioned. In patients with more than one event during follow-up, only
TABLE 2 Multivariable cox models for major adverse cardiac and cerebrovascular events (MACCE) separately for year 1 (all patients) and year
2 (patients MACCE-free in year 1)
Year 1 (n = 10 568) Year 2 (n = 9209)
Baseline variable HR 95% CI P value HR 95% CI P value
Age (per 10 years) 1.36 1.25-1.49 <0.001 1.28 1.15-1.43 <0.001
Male sex 1.32 1.07-1.64 0.01 1.38 1.04-1.83 0.02
Education: No formal 1 — — 1 — —
Primary 0.77 0.55-1.08 0.13 0.95 0.60-1.51 0.84
Secondary 0.72 0.51-1.01 0.06 0.67 0.41-1.09 0.11
University 0.72 0.47-1.09 0.12 0.80 0.46-1.40 0.44
Region: Northern Europe 1 — — 1 — —
Eastern Europe 1.87 1.47-2.39 <0.001 1.00 0.71-1.40 0.99
Latin America 1.58 1.21-2.04 <0.001 1.49 1.09-2.05 0.01
Southern Europe 1.17 0.90-1.52 0.24 1.00 0.71-1.38 0.99
Ejection fractiona:<40% 1.65 1.27-2.13 <0.001 1.34 0.92-1.94 0.13
<30% 2.84 2.08-3.90 <0.001 1.45 0.82-2.54 0.20
BMI <20 kg/m2 1.71 1.02-2.85 0.04 1.62 0.75-3.49 0.22
No coronary revascularization or thrombolysis 1.59 1.31-1.93 <0.001 1.30 1.01-1.68 0.04
Creatinine (per log unit if ≥1.2 mg/dL)a,b 2.14 1.61-2.85 <0.001 1.64 1.05-2.56 0.03
EQ-5D: 0 1 — — 1 — —
1 1.11 0.86-1.43 0.43 0.86 0.62-1.20 0.37
≥2 1.41 1.14-1.75 0.002 1.22 0.93-1.60 0.14
Hemoglobina < 11 g/dL 1.37 0.98-1.92 0.06 1.55 1.00-2.41 0.05
<13 g/dL 1.26 1.01-1.57 0.04 1.33 0.99-1.78 0.06
≥13 g/dL 1 — — 1 — —
Prior cardiac disease 1.44 1.18-1.76 <0.001 2.01 1.56-2.59 <0.001
Previous COPD 1.54 1.18-2.01 0.002 1.92 1.37-2.68 <0.001
Glucose (per 100 mg/dL if ≥140 mg/dL)a,c 1.20 1.06-1.36 0.004 1.29 1.09-1.53 0.003
On diuretics at discharge 1.22 0.98-1.51 0.07 1.39 1.05-1.84 0.02
On aldosterone inhibitor at discharge 1.39 1.09-1.78 0.008 1.30 0.91-1.88 0.15
In-hospital cardiac complications 1.28 1.05-1.57 0.02 1.26 0.96-1.65 0.10
Diagnosis of STEMI 1.02 0.83-1.25 0.86 0.91 0.70-1.19 0.50
Killip class: I 1 — — 1 — —
II 1.32 1.02-1.70 0.03 0.76 0.50-1.15 0.19
III–IV 1.30 0.93-1.82 0.13 1.09 0.68-1.74 0.72
MACCE, defined as death, non-fatal MI and non-fatal stroke.
a At admission.
b Example, creatinine 2.4 mg/dL, HR is 2.14 compared with creatinine ≤1.2 mg/dL during year 1 follow-up.
c Example, glucose 240 mg/dL, HR is 1.2 compared with glucose ≤140 mg/dL during year 1 follow-up.
Abbreviations: BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; EQ-5D, EuroQol five-dimension question-
naire; HR, hazard ratio; MI, myocardial infarction; STEMI, ST-segment elevation myocardial infarction.
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the first event was considered. Most patients were censored during
the last follow-up interview (24 months 2 weeks). We did not evalu-
ate the influence of discharge medication and length of secondary
prevention therapies on outcomes. The selection of site investigators
was not random and central adjudication of outcomes was not used in
the EPICOR study. Some comparisons in risk factors between year
1 and 2 might be underpowered and hence some true associations
may have been undetected. The EPICOR 2-year risk score predicts
mortality but not non-fatal outcomes. A major strength of our study is
that we assessed a comprehensive set of patients and practice pat-
terns, as this analysis derives from a large international database that
includes subjects from different health systems treated in different
hospital settings. We also assessed various risk factors which were
previously described to predict 2-year mortality in the same
population.
5 | CONCLUSIONS
In post-ACS, there is a continuous risk for MACCE during the 2-year
follow-up. Event rate for MACCE was higher in year 1 than in year
2, primarily driven by a higher mortality rate in year 1. Rates of non-
fatal MI and stroke did not change between years 1 and 2. Several
easily measured patient characteristics were predictive for ACS-
related MACCE during both years 1 and 2, although some lost their
predictive value over time. As we were unable to identify specific risk
factors for events occurring after an uneventful first year, secondary
prevention measures should therefore be continued especially in
higher-risk patients who can be identified by the EPICOR 2-year mor-
tality risk score.
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